Abstract
Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.
Keywords: Parkinson disease, cognitive impairment, dementia, Alzheimer disease, Demenita with Lewy bodies
Current Topics in Medicinal Chemistry
Title: Cognitive Impairment and Dementia in Patients with Parkinson Disease
Volume: 9 Issue: 10
Author(s): James B. Leverenz, Joseph F. Quinn, Cyrus Zabetian, Jing Zhang, Kathleen S. Montine and Thomas J. Montine
Affiliation:
Keywords: Parkinson disease, cognitive impairment, dementia, Alzheimer disease, Demenita with Lewy bodies
Abstract: Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.
Export Options
About this article
Cite this article as:
Leverenz B. James, Quinn F. Joseph, Zabetian Cyrus, Zhang Jing, Montine S. Kathleen and Montine J. Thomas, Cognitive Impairment and Dementia in Patients with Parkinson Disease, Current Topics in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/156802609789378218
DOI https://dx.doi.org/10.2174/156802609789378218 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanochannel Systems for Personalized Therapy and Laboratory Diagnostics
Current Pharmaceutical Biotechnology Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Nanoemulsions: A Better Approach for Antidiabetic Drug Delivery
Current Diabetes Reviews The Role of the Cytoskeleton in the Life Cycle of Viruses and Intracellular Bacteria: Tracks, Motors, and Polymerization Machines
Current Drug Targets - Infectious Disorders The HCMV Chemokine Receptor US28 is a Potential Target in Vascular Disease
Current Drug Targets - Infectious Disorders Intracellular Delivery: Exploiting Viral Membranotropic Peptides
Current Drug Metabolism Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Can Correcting the ΔF508-CFTR Proteostasis-Defect Rescue CF Lung Disease?
Current Molecular Medicine Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Blood-Brain Barrier Alterations in MDX Mouse, An Animal Model of the Duchenne Muscular Dystrophy
Current Neurovascular Research Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry Suramin Attenuated Inflammation and Reversed Skin Tissue Damage in Experimentally Induced Atopic Dermatitis in Mice
Inflammation & Allergy - Drug Targets (Discontinued) Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dopaminergic Enhancement of Cognitive Function
Current Pharmaceutical Design Effects of Acute and Chronic Treatment of Novel Psychotropic Drug, 8- (Trifluoromethyl)-1, 2, 3, 4, 5-benzopentathiepin-6-amine Hydrochloride (TC-2153), on the Behavior of Zebrafish (Danio Rerio): A Comparison with Fluoxetine
Letters in Drug Design & Discovery A Review of Developments in Brain Stimulation and the Treatment of Psychiatric Disorders
Current Psychiatry Reviews The Neuropsychological Hypothesis of Antidepressant Drug Action Revisited
CNS & Neurological Disorders - Drug Targets